Newsletter
Marksans Pharma’s wholly-owned subsidiary, Relonchem, has received marketing authorisation from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) for Exemestane 25 mg film-coated tablets.
In simple terms, these tablets are used primarily for the treatment of breast cancer in women.
Why it matters: according to the WHO, in 2022, around 2.3 million women were diagnosed with breast cancer, and 670,000 lost their lives to the disease globally.
This trend aligns closely with Marksans Pharma’s strategy to expand its oncology and specialty medicines portfolio across key international markets. By securing this approval, the company can tap into the growing UK oncology segment, a high-value market with strong demand for affordable generic cancer therapies.
